A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Ascending Dose Administration to Patients With Suspected Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)
Latest Information Update: 15 May 2024
At a glance
- Drugs ION 455 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 08 May 2024 Status changed from recruiting to discontinued.
- 25 Aug 2023 Planned End Date changed from 28 Jun 2024 to 25 Oct 2024.
- 22 May 2023 New trial record